サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：放射線皮膚炎の市場規模、シェア、動向分析レポート：製品別（局所、副腎皮質ホルモン、親水性クリーム、抗生物質、ドレッシング、ヒドロゲル＆ハイドロコロイド）、流通チャネル別、地域別、セグメント別予測、2023年～2030年
市場調査レポート
商品コード
1171046

放射線皮膚炎の市場規模、シェア、動向分析レポート：製品別（局所、副腎皮質ホルモン、親水性クリーム、抗生物質、ドレッシング、ヒドロゲル＆ハイドロコロイド）、流通チャネル別、地域別、セグメント別予測、2023年～2030年

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Corticosteroids, Hydrophilic Creams, Antibiotics, Dressings, Hydrogel & Hydrocolloid), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
放射線皮膚炎の市場規模、シェア、動向分析レポート：製品別（局所、副腎皮質ホルモン、親水性クリーム、抗生物質、ドレッシング、ヒドロゲル＆ハイドロコロイド）、流通チャネル別、地域別、セグメント別予測、2023年～2030年
出版日: 2022年11月22日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚炎市場の成長と動向

米国Grand View Research社の最新レポートによると、放射性皮膚炎の世界市場規模は2030年までに5億5710万米ドルに達すると予測されています。同市場は2023年から2030年にかけてCAGR3.9%で拡大すると予測されています。放射線療法を受けるがん患者の増加により、市場はかつてない速度で成長すると予想されます。新興国と先進国の両方における患者のアンメット・メディカル・ニーズも、放射線皮膚炎治療の需要を高める要因となっています。また、糖尿病や肥満の増加に伴い、がんに罹患する可能性が高くなります。この要因は、おそらく放射性皮膚炎の症例を増やし、放射線治療の必要性を高めると思われます。さらに、アルコール摂取量の増加や喫煙は、さらなるがんの危険因子であり、放射線皮膚炎治療薬の需要を確実に増加させると思われます。

COVID-19の大流行は、放射線皮膚炎市場に大きな影響を及ぼしています。世界的に、多くのがんセンターは、パンデミックの間にがんと診断され、治療された患者数の大幅な減少を報告しています。世界中の病院では、COVID-19のパンデミックを支援するためのシフトがあったため、放射線治療が減少しました。しかし、2020年第3四半期までに規制が緩和されたことにより、放射線治療が増加し始め、放射線皮膚炎市場の成長をもたらしました。

予測期間中の収益と成長率では、アジア太平洋地域が市場全体を支配しています。増加するがん研究活動、進歩するヘルスケアインフラ、支出の存在は、このセグメントのより大きなシェアを獲得するための要因の一部です。また、アンメットニーズに応えるため、アジア太平洋地域は予測期間中に収益性の高い成長を遂げる可能性があります。第2位は北米です。放射線熱傷の発生率の増加や、皮膚移植や代用品の需要の高さが、この市場の成長をさらに促進すると予想されます。

放射線皮膚炎市場レポートハイライト

2022年の製品分野では、外用剤分野が最大のシェアを獲得しました。この圧倒的なシェアは、入手のしやすさ、利便性の高さ、経口製品に対する優位性に起因するものです。また、外用剤は患者の要求に応じてクリーム、ゲル、軟膏などさまざまな剤形で利用できるため、飛躍的な成長が見込まれています。

2022年、薬局数の増加に伴い、流通チャネル別では小売薬局が大きな割合を占めています。病院での処方箋のうち、小売薬局が占める割合は大きい

アジア太平洋地域は、がん患者数が多いことから、同地域で最も高いシェアを占めています。

北米は、潜在的な成長機会を促進する大規模な研究開発活動により、2番目に大きなシェアを占めています。また、北米では治療効果の高い製品が入手可能であることも、高いシェアを獲得している主な要因の一つです。

競合他社は、製品の上市、販売契約、戦略的提携などの戦略を実施し、それぞれの市場シェアを大きく伸ばしています。

目次

第1章 調査手法と範囲

  • 地域ごとの市場計算
    • 地域ごとの市場：基本推定
    • 世界市場：CAGR計算
  • 地域別セグメントシェア計算
  • 二次情報一覧

第2章 エグゼクティブサマリー

第3章 放射線皮膚炎市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場促進要因分析
  • 市場抑制要因分析
  • 浸透と成長の見通しのマッピング
  • 放射線皮膚炎市場SWOT分析、要因別（政治と法律、経済と技術）
  • 業界分析- ポーターズ
  • COVID-19影響分析

第4章 放射線皮膚炎市場：製品推定・動向分析

  • 放射線皮膚炎市場：製品変動分析
  • 局所
    • コルチコステロイド
    • 親水性クリーム
    • 抗生物質
    • その他
  • 経口
  • 被覆材
    • ハイドロゲル＆ハイドロコロイドドレッシング
    • スティングバリアフィルムなし
    • 蜂蜜含浸ガーゼ
    • シリコーン被覆ドレッシング
    • その他

第5章 放射線皮膚炎市場：流通チャネルの推定・動向分析

  • 放射線皮膚炎市場：流通チャネルの変動分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 放射線皮膚炎市場：製品および流通チャネル別の地域推定・動向分析

  • 放射線皮膚炎の地域別市場シェア、2022年および2030年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 戦略的枠組み
  • 市場参加の分類
  • 企業プロファイル
    • Stratpharma AG
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Smith &Nephew
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Molnlycke Health Care AB
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Derma Sciences Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • ConvaTec Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • BMG Pharma SRL
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Acelity
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • 3M
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
    • Alliqua BioMedical
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations

List of Figures

  • FIG. 1 Market outlook
  • FIG. 2 Market segmentation & scope
  • FIG. 3 Market driver relevance analysis (Current & future impact)
  • FIG. 4 Market restraint relevance analysis (Current & future impact)
  • FIG. 5 Penetration & growth prospect mapping
  • FIG. 6 SWOT Analysis, By Factor (Political & legal, economic and technological)
  • FIG. 7 Porter's Five Forces Analysis
  • FIG. 8 Radiodermatitis market, product outlook: Key takeaways
  • FIG. 9 Radiodermatitis market: Product movement analysis
  • FIG. 10 Global topical market, 2018 - 2030 (USD Million)
  • FIG. 11 Global corticosteroid market, 2018 - 2030 (USD Million)
  • FIG. 12 Global hydrophilic creams market, 2018 - 2030 (USD Million)
  • FIG. 13 Global antibiotics market, 2018 - 2030 (USD Million)
  • FIG. 14 Global others market, 2018 - 2030 (USD Million)
  • FIG. 15 Global oral market, 2018 - 2030 (USD Million)
  • FIG. 16 Global dressings market, 2018 - 2030 (USD Million)
  • FIG. 17 Global hydrogel & hydrocolloid dressing market, 2018 - 2030 (USD Million)
  • FIG. 18 Global no sting barrier film market, 2018 - 2030 (USD Million)
  • FIG. 19 Global honey impregnated gauze market, 2018 - 2030 (USD Million)
  • FIG. 20 Global silicone coated dressings market, 2018 - 2030 (USD Million)
  • FIG. 21 Global others market, 2018 - 2030 (USD Million)
  • FIG. 22 Radiodermatitis market, distribution channel outlook: Key takeaways
  • FIG. 23 Radiodermatitis market: Distribution channel movement analysis
  • FIG. 24 Global hospital pharmacies market, 2018 - 2030 (USD Million)
  • FIG. 25 Global retail pharmacies market, 2018 - 2030 (USD Million)
  • FIG. 26 Global online pharmacies market, 2018 - 2030 (USD Million)
  • FIG. 27 Regional market place: Key takeaways
  • FIG. 28 Regional outlook, 2022 & 2030
  • FIG. 29 U.S. Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 30 Canada radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 31 Germany Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 32 U.K. radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 33 Germany Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 34 France radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 35 Italy Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 36 Spain radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 37 Denmark Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 38 Sweden radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 39 Norway Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 40 China radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 41 Japan Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 42 India radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 43 Australia Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 44 South Korea radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 45 Thailand Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 46 Brazil radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 47 Mexico Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 48 Argentina radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 49 South Africa Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 50 Saudi Arabia radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 51 UAE Radiodermatitis market, 2018 - 2030 (USD Million)
  • FIG. 52 Kuwait radiodermatitis market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-857-2

Radiodermatitis Market Growth & Trends:

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.9% from 2023 to 2030. The market is expected to grow at an unprecedented rate owing to the growing prevalence of cancer patients undergoing radiation therapy. The unmet medical needs of patients in both emerging and developed nations are another factor that increases the demand for radiodermatitis treatment. As the prevalence of diabetes and obesity increases, these individuals are more likely to suffer from cancer. This factor is probably going to increase the cases of radiodermatitis and increase the need for radiation therapy. Furthermore, higher consumption of alcohol and smoking are additional cancer risk factors, which will certainly increase demand for radiodermatitis medications.

The COVID-19 pandemic has a significant impact on the radiodermatitis market. Various regions imposed restrictions or lockdowns of varying severity implemented to curb the pandemic, with different outcomes.Globally, many cancer centers have reported substantial decreases in the number of patients diagnosed with and treated for cancer during the pandemic. Hospitals across the globe have decreased radiotherapy treatment as there was a shift to support the COVID-19 pandemic. However, with the ease of the restrictions by the 3rd quarter of 2020, radiotherapy treatment started to increase which resulted in the growth of the radiodermatitis market.

Asia Pacific dominated the overall market in terms of revenue and growth rate during the forecast period. The presence of increasing cancer research activities, advancing healthcare infrastructure, and expenditure are some of the factors responsible for garnering a greater share of the segment. As a result of unmet patient needs, Asia Pacific is also likely to have profitable expansion over the course of the projection period. The market's second-largest share was accounted for by North America. The increasing incidence of radiation burns along with the high demand for skin grafts and substitutes is expected to further drive the growth of this market.

Radiodermatitis Market Report Highlights:

  • The topical products segment captured the largest share in the product segment in 2022. The dominant share is attributable to ease in availability, greater convenience, and superiority over oral products. Topical products are also anticipated to grow at an exponential rate owing to their availability in various formulations such as creams, gels, and ointments according to the requirement of the patient
  • In 2022, the retail pharmacies segment accounted for a substantial share of the distribution channel segment owing to the rising number of pharmacies. The retail pharmacies may capture large percent of prescriptions written in the hospital
  • Due to the high number of cancer patients in this area, Asia Pacific held the highest share of the market
  • North America held the second largest share owing to extensive R&D activities that have fueled high-potential growth opportunities. In addition, the availability of therapeutically advanced products across North America is one of the major factors contributing toward its high share
  • The competition is marked by major players undertaking strategies such as product launches, distribution agreements, and strategic collaborations that have led to significant growth in their respective market share

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region-wise market: Base estimates
    • 1.1.2 Global market: CAGR calculation
  • 1.2 Region-Based Segment Share Calculation
  • 1.3 List of Secondary Sources

Chapter 2 Executive Summary

Chapter 3 Radiodermatitis Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
  • 3.3 Market Restraint Analysis
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 Radiodermatitis Market - SWOT Analysis, By Factor (Political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's
  • 3.7 COVID-19 Impact Analysis

Chapter 4 Radiodermatitis Market: Product Estimates & Trend Analysis

  • 4.1 Radiodermatitis Market: Product Movement Analysis
  • 4.2 Topical
    • 4.2.1 Topical Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2 Corticosteroids
      • 4.2.2.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3 Hydrophilic Creams
      • 4.2.3.1 Hydrophilic Creams Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.4 Antibiotics
      • 4.2.4.1 Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.5 Others
      • 4.2.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.3 Oral
    • 4.3.1 Oral Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.4 Dressings
    • 4.4.1 Dressings Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2 Hydrogel & Hydrocolloid Dressing
      • 4.4.2.1 Hydrogel & Hydrocolloid Dressing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3 No Sting Barrier Film
      • 4.4.3.1 No Sting Barrier Film Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4 Honey Impregnated Gauze
      • 4.4.4.1 Honey Impregnated Gauze Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5 Silicone Coated Dressings
      • 4.4.5.1 Silicone Coated Dressings Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6 Others
      • 4.4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1 Radiodermatitis Market: Distribution Channel Movement Analysis
  • 5.2 Hospital Pharmacies
    • 5.2.1 Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.3 Retail Pharmacies
    • 5.3.1 Retail Pharmacies Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4 Online Pharmacies
    • 5.4.1 Online Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Radiodermatitis Market: Regional Estimates & Trend Analysis, by Product & Distribution Channel

  • 6.1 Radiodermatitis Market Shares By Region, 2022 & 2030
  • 6.2 North America
    • 6.2.1 North America Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
    • 6.2.2 North America Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.2.3 U.S.
      • 6.2.3.1 U.S. Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.2.3.2 U.S. Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.2.4 Canada
      • 6.2.4.1 Canada Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.2.4.2 Canada Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
    • 6.3.2 Europe Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.3 U.K.
      • 6.3.3.1 U.K. radiodermatitis Market Estimates And Forecasts, 2018 - 2030(USD Million)
      • 6.3.3.2 U.K. Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.3.3 U.K. Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.4 Germany
      • 6.3.4.1 Germany Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.4.2 Germany Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.5 France
      • 6.3.5.1 France Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.5.2 France Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.6 Italy
      • 6.3.6.1 Italy Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.6.2 Italy Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.7 Spain
      • 6.3.7.1 Spain Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.7.2 Spain Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.8 Denmark
      • 6.3.8.1 Denmark Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.8.2 Denmark Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.9 Sweden
      • 6.3.9.1 Sweden Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.9.2 Sweden Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.3.10 Norway
      • 6.3.10.1 Norway Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.3.10.2 Norway Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
    • 6.4.2 Asia Pacific Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Japan Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.3.2 Japan Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.4 China
      • 6.4.4.1 China Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.4.2 China Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.5 India
      • 6.4.5.1 India Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.5.2 India Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.6 Australia
      • 6.4.6.1 Australia Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.6.2 Australia Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.7 South Korea
      • 6.4.7.1 South Korea Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.7.2 South Korea Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.4.8 Thailand
      • 6.4.8.1 Thailand Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.4.8.2 Thailand Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
    • 6.5.2 Latin America Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.5.3 Brazil
      • 6.5.3.1 Brazil Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.5.3.2 Brazil Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.5.4 Mexico
      • 6.5.4.1 Mexico Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.5.4.2 Mexico Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.5.5 Argentina
      • 6.5.5.1 Argentina Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.5.5.2 Argentina Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
    • 6.6.2 MEA Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.6.3 South Africa
      • 6.6.3.1 South Africa Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.6.3.2 South Africa Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.6.4 Saudi Arabia
      • 6.6.4.1 Saudi Arabia Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.6.4.2 Saudi Arabia Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.6.5 UAE
      • 6.6.5.1 UAE Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.6.5.2 UAE Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)
    • 6.6.6 Kuwait
      • 6.6.6.1 Kuwait Radiodermatitis Market, by Product, 2018 - 2030 (USD Million)
      • 6.6.6.2 Kuwait Radiodermatitis Market, by Distribution Channel, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Market Participation Categorization
  • 7.3 Company Profiles
    • 7.3.1 Stratpharma AG
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
    • 7.3.2 Smith & Nephew
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product Benchmarking
      • 7.3.2.4 Strategic initiatives
    • 7.3.3 Molnlycke Health Care AB
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product Benchmarking
      • 7.3.3.4 Strategic initiatives
    • 7.3.4 Derma Sciences Inc.
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product Benchmarking
      • 7.3.4.4 Strategic initiatives
    • 7.3.5 ConvaTec Inc.
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives
    • 7.3.6 BMG Pharma S.R.L.
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 Acelity
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
    • 7.3.8 3M
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product Benchmarking
    • 7.3.9 Alliqua BioMedical
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial performance
      • 7.3.9.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives